Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 21

Cited In for PubMed (Select 19362955)

1.

XRCC1 genetic polymorphisms and sensitivity to platinum-based drugs in non-small cell lung cancer: an update meta-analysis based on 4708 subjects.

Gu AQ, Wang WM, Chen WY, Shi CL, Lu JH, Han JQ.

Int J Clin Exp Med. 2015 Jan 15;8(1):145-54. eCollection 2015.

2.

Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?

Roco A, Cayún J, Contreras S, Stojanova J, Quiñones L.

Front Genet. 2014 Nov 14;5:391. doi: 10.3389/fgene.2014.00391. eCollection 2014. Review.

3.

ERCC1 Cys8092Ala and XRCC1 Arg399Gln polymorphisms predict progression-free survival after curative radiotherapy for nasopharyngeal carcinoma.

Jin H, Xie X, Wang H, Hu J, Liu F, Liu Z, Zhou J, Zhang Y, Xi X, Hu B, Liao Y, Tang J.

PLoS One. 2014 Jul 15;9(7):e101256. doi: 10.1371/journal.pone.0101256. eCollection 2014.

4.

Inter-individual variation in DNA repair capacity: a need for multi-pathway functional assays to promote translational DNA repair research.

Nagel ZD, Chaim IA, Samson LD.

DNA Repair (Amst). 2014 Jul;19:199-213. doi: 10.1016/j.dnarep.2014.03.009. Epub 2014 Apr 26.

PMID:
24780560
5.

Polymorphisms in XPD gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients: a meta-analysis of 24 studies.

Qin Q, Zhang C, Yang X, Zhu H, Yang B, Cai J, Cheng H, Ma J, Lu J, Zhan L, Liu J, Liu Z, Xu L, Sun X.

PLoS One. 2013 Nov 15;8(11):e79864. doi: 10.1371/journal.pone.0079864. eCollection 2013.

6.

Predictive value of XPD polymorphisms on platinum-based chemotherapy in non-small cell lung cancer: a systematic review and meta-analysis.

Qiu M, Yang X, Hu J, Ding X, Jiang F, Yin R, Xu L.

PLoS One. 2013 Aug 19;8(8):e72251. doi: 10.1371/journal.pone.0072251. eCollection 2013. Review.

7.

Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.

Figg WD, Chau CH, Madan RA, Gulley JL, Gao R, Sissung TM, Spencer S, Beatson M, Aragon-Ching J, Steinberg SM, Dahut WL.

Clin Genitourin Cancer. 2013 Sep;11(3):229-37. doi: 10.1016/j.clgc.2013.04.007. Epub 2013 May 17.

8.

ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin.

Tiseo M, Bordi P, Bortesi B, Boni L, Boni C, Baldini E, Grossi F, Recchia F, Zanelli F, Fontanini G, Naldi N, Campanini N, Azzoni C, Bordi C, Ardizzoni A; Bio-FAST trial group.

Br J Cancer. 2013 Apr 30;108(8):1695-703. doi: 10.1038/bjc.2013.127. Epub 2013 Apr 2.

9.

Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population.

Hong W, Wang K, Zhang YP, Kou JY, Hong D, Su D, Mao WM, Yu XM, Xie FJ, Wang XJ.

J Zhejiang Univ Sci B. 2013 Mar;14(3):207-15. doi: 10.1631/jzus.B1200101.

10.

ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer.

Vaezi A, Feldman CH, Niedernhofer LJ.

Pharmgenomics Pers Med. 2011;4:47-63. doi: 10.2147/PGPM.S20317. Epub 2011 Jul 20.

11.

XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies.

Chen J, Zhao QW, Shi GM, Wang LR.

J Zhejiang Univ Sci B. 2012 Nov;13(11):875-83. doi: 10.1631/jzus.B1200083. Review.

12.

Association between eIF3α polymorphism and severe toxicity caused by platinum-based chemotherapy in non-small cell lung cancer patients.

Xu X, Han L, Duan L, Zhao Y, Yang H, Zhou B, Ma R, Yuan R, Zhou H, Liu Z.

Br J Clin Pharmacol. 2013 Feb;75(2):516-23. doi: 10.1111/j.1365-2125.2012.04379.x.

13.

Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients.

Yin JY, Huang Q, Zhao YC, Zhou HH, Liu ZQ.

PLoS One. 2012;7(6):e38150. doi: 10.1371/journal.pone.0038150. Epub 2012 Jun 26.

14.

Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis.

Cui Z, Yin Z, Li X, Wu W, Guan P, Zhou B.

BMC Cancer. 2012 Feb 17;12:71. doi: 10.1186/1471-2407-12-71. Review.

15.

Translational medicine and reliability of single-nucleotide polymorphism studies: can we believe in SNP reports or not?

Valachis A, Mauri D, Neophytou C, Polyzos NP, Tsali L, Garras A, Papanikolau EG.

Int J Med Sci. 2011;8(6):492-500. Epub 2011 Aug 24.

16.

Systematic evaluation of genetic variants in three biological pathways on patient survival in low-stage non-small cell lung cancer.

Pankratz VS, Sun Z, Aakre J, Li Y, Johnson C, Garces YI, Aubry MC, Molina JR, Wigle DA, Yang P.

J Thorac Oncol. 2011 Sep;6(9):1488-95. doi: 10.1097/JTO.0b013e318223bf05.

17.

Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy.

Li Y, Sun Z, Cunningham JM, Aubry MC, Wampfler JA, Croghan GA, Johnson C, Wu D, Aakre JA, Molina J, Wang L, Pankratz VS, Yang P.

Clin Cancer Res. 2011 Jun 1;17(11):3830-40. doi: 10.1158/1078-0432.CCR-10-2877.

18.

CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients.

Park SR, Kong SY, Nam BH, Choi IJ, Kim CG, Lee JY, Cho SJ, Kim YW, Ryu KW, Lee JH, Rhee J, Park YI, Kim NK.

Br J Cancer. 2011 Mar 29;104(7):1126-34. doi: 10.1038/bjc.2011.24. Epub 2011 Mar 1.

19.

The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity.

Gao R, Reece K, Sissung T, Reed E, Price DK, Figg WD.

Mutat Res. 2011 Mar 15;708(1-2):21-7. doi: 10.1016/j.mrfmmm.2011.01.002. Epub 2011 Feb 16.

20.

Nucleotide excision repair deficiency is intrinsic in sporadic stage I breast cancer.

Latimer JJ, Johnson JM, Kelly CM, Miles TD, Beaudry-Rodgers KA, Lalanne NA, Vogel VG, Kanbour-Shakir A, Kelley JL, Johnson RR, Grant SG.

Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21725-30. doi: 10.1073/pnas.0914772107. Epub 2010 Nov 30.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk